R habdomyosarcoma (RMS) is the most common malignant soft-tissue mesenchymal tumor in childhood, representing 4% of all solid tumors in children. 1 Approximately one third of RMS arises in the head and neck. 2 Because of their specific outcome and particular local therapy, RMS in this site have been classified into 3 different anatomic groups: nonparameningeal orbital tumors (NPM ORMS), nonorbital cranial parameningeal (PM) tumors, and nonparameningeal (NPM) tumors of the head and neck. Orbital rhabdomyosarcomas (ORMS) mostly arise from extraocular muscles, but can also arise from the eyelids. Nonparameningeal orbital tumors, which represent 10% of all RMS, are considered to have a favorable outcome with an expected 5-year overall survival (OS) rate >85%, 2 with therapy including systemic chemotherapy and local therapy mostly orbital external beam radiotherapy. PM extension of an ORMS accounts for 5% to 11% of all PM primaries and is associated with a specific OS of 76.9% (64.1% to 85.6%). [3] [4] [5] These tumors may present local extension to PM structures: osteolysis of the orbital roof or sphenoid, invasion of the optic nerve, and maxillary or ethmoid sinus, and are then classified as "parameningeal" primary ORMS (PM ORMS). Long-term effects after treatment of NPM ORMS have already been described. 3 The aim of this study was to describe the longterm outcome of a large cohort of 95 pediatric patients treated for PM or NPM ORMS in a single center according to a conservative strategy. The primary objective was to describe the outcome and analyze prognostic factors of this primary tumor to determine the best treatment strategy.
MATERIALS AND METHODS

Study Population
The single-center retrospective analysis included patients diagnosed with localized ORMS with or without PM extension, under the age of 20, and treated between 1975 and 2010 at the Institut Curie in Paris according to a conservative strategy. No specific histologic review was performed for this study, but a central panel review had to be performed for all patients included in protocols. 2, 6 Histologic subtypes were identified as alveolar in the presence of any zone of alveolar histology or a specific fusion transcript on molecular biology, or nonalveolar (embryonal, botryoid, and not otherwise specified). 7 Clinical staging was defined according to the SIOPInternational Union Against Cancer TNM system 8 : T1, tumors limited to the compartment of origin; T2, tumors extending beyond the tissue of origin. Lymph node involvement was evaluated clinically or by imaging, and confirmed by cytology or histology when necessary. Disease staging consisted of 99m Technetium scan and bone marrow evaluation (bone marrow aspirations and biopsies). Postoperative staging was classified according to the International Rhabdomyosarcoma Staging (IRS) grouping system. 9 Briefly, IRS I corresponds to complete tumor resection with histologically free margins, IRS II corresponds to a macroscopic resection but with invaded margins on histology, and IRS III corresponds to macroscopic residual tumor. Biopsy alone with no surgical resection was also considered to be IRS III.
The study was approved by the French personal data protection authority (Commission Nationale Informatique et Liberte´) (CNIL).
Treatment
Chemotherapy Regimens
All patients received chemotherapy as part of or according to the international protocol recommended at the time of diagnosis: RMS-75, MMT-84, MMT-89, MMT-95, and RMS-05 studies. 2, 6, [10] [11] [12] Some patients were treated outside of the context of current protocols for various reasons. The main chemotherapy regimens used are reported in Table 1 .
Details of the MMT-84 protocol have been published previously. 6 The treatment strategy was determined by the extent of primary surgery. Patients with complete primary resection (IRS-group I) received chemotherapy consisting of 3 courses of Ifosfamide, Vincristine, and Dactinomycin (IVA) in MMT-84, but only 4 courses of VA in the MMT-89, 95, and 05 protocols (Table 1) . Incomplete primary resection (IRS groups II and III) was followed by 6 to 10 courses of IVA in MMT-84, 6 courses in the MMT-89, and 9 courses in MMT-95 and RMS-05 protocols. Further local therapy was administered to patients who failed to achieve complete remission with primary surgery and/or adjuvant chemotherapy and to patients with unfavorable characteristics regardless of tumor response. Patients with partial response or progressive disease received second-line chemotherapy with cisplatin and doxorubicin (DP) in the MMT-84 protocol and Vincristine, Carboplatin, and Teniposide (or Etoposide) (VINCAEPI) in the MMT-89 protocol. All patients with either metastatic, node positive, or PM disease registered in the MMT-89 protocol were treated with intensified "6-drug" chemotherapy comprising IVA, Carboplatin, Epirubicin, and Vincristine (CEV) and Ifosfamide, Vincristine, and Etoposide (IVE). High-risk patients included in the MMT-95 or RMS-05 trials were randomized to receive IVA versus "6 drugs" or IVA versus IVA with doxorubicin (IVADo), respectively. 2, 13 The global strategy of local therapy for NPM RMS remained relatively constant over the years of the study. Initial surgery was only recommended for small orbital tumors when complete resection was expected, especially for eyelid primaries. For all other tumors, biopsy was mandatory at diagnosis. Baseline strategy consisted of initial neoadjuvant chemotherapy to reduce tumor volume and to evaluate tumor response. In the presence of favorable tumor characteristics, age below 10, small size tumor (< 5 cm), nonalveolar histology, NPM extension, and radiologic complete remission after 3 cycles of neoadjuvant chemotherapy, patients require no further local therapy to try to reduce total burden of local therapy. 1 Initial biopsy followed by systemic chemotherapy was recommended for localized PM ORMS. As this site is considered to be an unfavorable site, local therapy with external beam radiotherapy was systematically delivered. 12 Radiation therapy and/or surgery were also planned for patients with incomplete response after induction chemotherapy or with poor initial prognostic factors such as alveolar histology, large tumor, and/or PM extension. Treatment was applied by conventional fractionation with 1.8 Gy per day. Recommendations for patients with embryonal RMS and favorable features, in complete remission after induction chemotherapy, were to avoid radiation therapy as part of first-line treatment. When radiation therapy was administered, it was delivered to the entire orbit with a maximum dose of 36 Gy, especially in young children. In this case, the planning target volume was reduced to the initial tumor size and an additional margin of 1 cm, sparing, whenever possible, the lacrimal gland and other periorbital organs, such as cornea, lens, retina, optic nerve, and optic chiasm. Patients with favorable histology and radiologic complete remission following 3 cycles of induction chemotherapy received 41.4 Gy, patients with partial response (> 2/3 diameter reduction) received 45 Gy, and patients with minor partial response, stable or progressive disease received 50.4 Gy. Alveolar RMS should receive 41.4 to 50.4 + /À5.4 Gy. In patients with PM involvement, radiation therapy was delivered systematically and the fields were adapted to the initial extension. For ORMS with skull base erosion and/or cranial nerve palsy, radiation fields had to adequately cover the initial skull base erosion, but whole brain irradiation was not routinely performed. Finally, for RMS with an intracranial component, the target volume was defined according to the residual intracranial component at restaging before starting radiotherapy with an additional safety margin of 2 cm. The recommended dose for lymph node involvement was 41.4 Gy applied to the entire lymph node site.
Common strategies for local relapse were based on a combination of various multiagent chemotherapy regimens associated with sometimes aggressive, local therapy, surgery, and/or radiotherapy. For patients who had not previously received radiotherapy as part of first-line treatment, the recommendation was to deliver systematic orbital local irradiation, whereas the strategy for patients irradiated as part of first-line treatment was based on extensive or mutilating surgery (exenteration) when further irradiation was not possible, associated with second-line chemotherapy. 1 The definitive extent of surgery was reported as follows: tumor resection, enucleation, and exenteration. Data concerning diagnosis, treatments, and late effects were collected from retrospective chart review and were graded according to the Common Terminology Criteria for Adverse Effects (CTCAE v4). 14 
Response Assessment
Tumor response after chemotherapy was assessed by measuring 2 diameters on imaging (World Health Organization): complete remission or residual mass compatible with fibrosis (defined as a stable or regressing mass on imaging performed 6 mo later), 15 tumor residue, or progressive disease. 16 In doubtful cases, cytologic or histologic response assessment was performed to confirm remission.
Statistical Methods
Outcome was defined by OS and event-free survival (EFS). OS was calculated from diagnosis to death from any cause. Events for EFS were defined as tumor progression, relapse after complete remission, second malignancy, or death from any cause. Survival curves were calculated by the Kaplan-Meier method. 17 For univariate analysis, the statistical significance of each variable was first tested by the Log-rank test. 18 Multivariate analysis was then performed with the Cox proportional hazards models for OS and EFS. Multivariate analysis models were determined using the likelihood ratio test and a forward procedure.
RESULTS
Patient and Tumor Characteristics
Initial characteristics of the 95 patients are presented in Table 2 . Median age at diagnosis was 6 years (range, 8 mo to 19.5 y) and was not significantly different according to the PM status of the tumor. Approximately, 16% of patients had a family history of cancer. Median interval between first symptoms and histologic diagnosis was 36 days (range, 44 d to 1.9 y). Initial tumor extensions are described in Table 2 , which shows that PM extension was present in 25 patients (26%). "Other sites" are tumors considered to arise in the extraconal zone or eyelid. The right eye was affected significantly more frequently in PM ORMS (P < 0.04). Main clinical initial presentations are presented in Table 2 and mostly concern presence of an orbital mass (76%) and exophthalmos (61%). The "others" observed signs in 20 patients are ptosis (8 patients), decreased visual acuity (2 patients), ocular atrophy (1 patient), associated tuberous angioma (1 patient), binocular diplopia (2 patients), ocular flow (2 patients), eyelid edema (2 patients), pan uveitis (1 patient), and buphthalmos (1 patient). Exophthalmos with chemosis is the only clinical sign significantly more frequent in PM ORMS (P < 0.007).
Initial tumor imaging consisted of head and neck computed tomography scan (91.6% of patients) and/or head magnetic resonance imaging (45.7% of patients). Tumor characteristics at diagnosis are presented in Table 2 , and show that the majority of tumors were T2 (54%) and IRS III tumors (83%). Only 1 patient had regional neck lymph node involvement. Fifty-nine of the 79 IRS III patients had a biopsy at diagnosis and surgery was attempted in 20 patients. Only 18% of tumors (17 patients) had an alveolar histology. Molecular biology was performed on 68 tumor samples (70.8%) and revealed the presence of the recurrent specific transcript in 4 cases of alveolar histology tumors, including 2 PM ORMS. PM ORMS were significantly larger at diagnosis than NPM ORMS (P < 0.0001) ( Table 2) .
First-line Treatment Strategy
All patients received chemotherapy as first-line treatment, initiated after a median of 9 days (range, 0 to 144 d) after diagnosis. More than 88% of patients were included in an international protocol running at the time of treatment, whereas the remaining patients received slightly different treatments due to comorbidity or physician preferences. Details of the chemotherapy delivered are reported in Table 3 .
Thirty-six (38%) of the 95 patients underwent surgery, other than surgical biopsy, as part of first-line treatment. Surgery was mostly performed at diagnosis, with a mean interval of 1 day (range, 0 to 25 d) after diagnosis. Details of surgical procedures are reported in Table 3 . A total of 31 patients with a small initial tumor underwent primary tumor resection rather than biopsy, whereas the other 5 patients underwent primary mutilating surgery. No surgical resection was performed as part of first-line treatment in 62% of patients.
Radiation therapy is described in Tables 3 and 4 . Radiation therapy was initiated a median of 101 days (range, 1 to 238 d) after diagnosis, corresponding to its use as adjuvant therapy to improve local control in the case of an unfavorable initial pattern or inadequate tumor response. Indications for radiotherapy for the 78 patients (82%) were sometimes multiple and are listed in Table 4 . Only 2 patients with eyelid tumors were treated with brachytherapy. Radiation therapy as first-line local therapy was mostly indicated in patients with tumor characteristics or course considered to be unfavorable, as 92% of patients with a PM tumor, 94% of patients above 10 years, 100% of patients with a tumor >5 cm, 90% of patients not treated surgically, 88% of patients with a stage T2 tumor, and 94% of patients with an alveolar tumor were irradiated.
Remission, Survival, and Relapse
A total of 66 (69.8%) patients obtained complete radiologic tumor response after first-line treatment. A total of 24 (26%) patients had a tumor residue on the imaging assessment at the end of the treatment. However, only 8 patients presented further local progression: 2 patients during the first 6 months and 6 patients after 6 months of follow-up, suggesting that the residual mass corresponded to fibrosis in all 16 other patients. Events occurred in 32 patients, 23 patients with NPM-ORMS and 9 patients with PM-ORMS, corresponding to 29 local events (8 initial treatment failures and 21 relapses) and/or 7 cases of metastatic spread. Among the 8 patients classified as "initial treatment failures," 3 had early progressive disease at the end of therapy, 4 a tumor reevolution during the follow-up of a residual mass, and 1 an early relapse. Five of them died 8 to 24 months after initial diagnosis. Overall median time to relapse was 14.5 months and no relapses occurred 5 years after diagnosis. Nine of the 29 cases of local relapse occurred in nonirradiated patients and 20 occurred after radiation therapy. Metastases were significantly more frequent in patients with PM ORMS (P < 0.03). Second-line treatment for local relapses consisted of a combination of mutilating surgery (delayed exenteration in 4 patients), second-line chemotherapy such as ICE and IVE cycles (32 patients), and local radiation therapy when possible (14 patients). One-year and 5-year OS after relapse were 75% ± 7.8% and 57% ± 4%, respectively.
Median follow-up was 8.5 years (range, 7 mo to 24 y). At the time of last follow-up, a total of 82 patients were alive, 62 of whom were in first complete remission and 20 in subsequent remission after relapse. One patient had died from second malignancy. In summary, a total of 13 patients had died, from progression of RMS in 11 cases, secondary malignancy in 1 case, and an unspecified cause in 1 case. At the time of analysis, the 5-year actuarial EFS and OS were 65.4% ± 5.2% and 85.6% ± 3.9%, respectively, for the overall population study (Fig. 1) .
Prognostic Factors
On univariate analysis, 5-year EFS was significantly better for small tumors (< 5 cm) (70% ± 5.3% vs. 28% ± 1.5%, P < 0.0002) and for patients treated with radiation therapy as part of first-line treatment (71% ± 5.5% vs. 40% ± 12.2%, P = 0.015) ( Table 5 ). Moreover, a favorable trend in better survival was observed for young patients below 10 years of age (P = 0.09). In contrast, histology (alveolar vs. nonalveolar), TNM, and IRS stages had no significant impact on 5-year EFS (P > 0.88, P > 0.7, and P = 0.24, respectively). On multivariate analysis, initial tumor size remained a strong prognostic factor on EFS (relative risk [RR] = 5.3 [2.3 to 12], P < 0.00065) even after adjustment for radiation therapy as first-line treatment (RR = 7.5 [3.1 to 18.4], P = 0.0001). Radiation therapy as part of first-line local treatment was also a significant favorable prognostic factor on 5-year EFS after adjustment for patient and tumor characteristics (age, histology, TNM, and IRS stages) (RR = 0.3 [0.1 to 0.7], P < 0.015).
No statistically significant difference in terms of 5-year survival rates was observed between PM ORMS and NPM ORMS, although an unfavorable trend was observed for PM ORMS (Fig. 2, Table 5 ): 5-year EFS was not significantly different between the 2 groups (60% ± 10.4% vs. 67% ± 5.9%, P > 0.57), whereas 5-year OS tended to be better for NPM ORMS (90% ± 3.9% vs. 73% ± 9.6%, P = 0.066). The salvage gap (difference between EFS and OS) after relapse was therefore 70% for NPM ORMS and 31% for PM ORMS.
On univariate analysis, in addition to the unfavorable trend observed for PM tumors, tumor size at diagnosis had a significant negative impact on OS (89% ± 3.8% for tumors <5 cm vs. 61% ± 1.5% for tumors >5 cm, P < 0.002). The other prognostic factors analyzed were not statistically significant: age (P = 0.2), TNM and IRS stages (P = 0.44 and 0.98), histology (P = 0.41), or radiotherapy (P = 0.74). On multivariate analysis, initial tumor size remained statistically significant after adjustment for radiation therapy (RR = 7.2 [2 to 26.4], P < 0.0075), whereas radiation therapy as part of first-line treatment had no statistically significant impact on OS even after adjustment for tumor and treatment characteristics (P > 0.74).
DISCUSSION
This large study with long-term follow-up of children with ORMS shows that NPM ORMS can be considered to be a favorable RMS primary associated with a 5-year OS of 85.6% ± 3.9%, regardless of the initial treatment strategy, which is consistent with the data of the literature. 15 At diagnosis, ORMS is usually a strictly localized intraorbital tumor with a low risk of nodal involvement (only 1 case in our series) and distant metastases (only 1 patient, not included in this study, with visceral metastases observed during this study period). 19 The risk of tumor events after therapy depends on whether or not external beam radiotherapy is used as part of first-line therapy and on initial tumor size. The main tumor event is local progression of the orbital tumor: 92% of cases in our experience. 19, 20 In contrast with other RMS primaries, patients with relapses for NPM ORMS can often be cured with an expected high survival rate after relapse. 21 Treatment should therefore include aggressive second-line therapy using new chemotherapy regimens and local therapy such as orbital radiotherapy and/or extensive surgery when repeated irradiation is not feasible. 22 The efficacy of external beam radiotherapy in local control of ORMS has been demonstrated since 1956 by Lederman. 23 However, the indications and doses of radiation therapy have tended to become more limited over the last 20 years to significantly decrease local and systemic late effects of therapy, while maintaining the high OS rate: 96% in the IRS-III study. 3 In 2011, the results of the IRS group based on the D9602 protocol in patients with low-risk embryonal RMS showed that lower intensity chemotherapy and a lower irradiation dose, administered only to patients with a tumor residue after primary chemotherapy, did not impair EFS and OS that remained statistically equivalent. In the North American group, full-dose irradiation was delivered in case of poor response to initial chemotherapy. 24 Local relapse was more frequent in nonirradiated patients, but was curable without jeopardizing the final OS rate, by using radiotherapy as second-line local treatment in combination with second-line chemotherapy. 11 These results confirm the international meta-analysis based on 306 patients, which showed similar OS rates in these various collaborative groups regardless of the strategy using local irradiation as part of first-line treatment. 15 A similar finding was observed in our population, as radiation therapy was a significant independent prognostic factor for improved 5-year EFS, but had no statistically significant impact on OS. However, this difference in outcome may also be influenced by the fact that patients treated with radiation therapy as part of first-line treatment were more likely to present unfavorable tumor patterns and possibly different tumor biology and behavior. It may be taken into account that this absence of difference in outcome for patients treated with radiation therapy as part of first-line treatment that were more likely to present unfavorable tumor patterns argues for radiotherapy to improve EFS in this high-risk population.
In our population, separate analysis of the impact of PM extension showed no significant difference of EFS between the 2 groups (ORMS PM 60.3% ± 10.4% vs. ORMS NPM 62.7% ± 5.9%, P > 0.57), whereas OS tended to be better in children with NPM tumors (90% ± 3.9% vs. 72.7% ± 9.6%, P = 0.066). These data suggest that relapses of PM tumors are less readily curable by second-line treatment, probably because radiation therapy had already been delivered during first-line treatment due to the presence of PM involvement, and therefore cannot be used as a salvage option for relapse in the vast majority of patients. Moreover, tumor events in ORMS PM are more frequently distant metastasis and therefore difficult to cure (data not shown). Systematic irradiation of patients with PM ORMS therefore seems to be recommended in an attempt to improve OS in this population. 12 In conclusion, this study demonstrated similar global long-term outcome results (5 y EFS and OS) to those reported in the literature. Large initial tumor size is the most important risk factor on outcome. Older age at diagnosis and initial PM extension also tend to influence survival. These 3 parameters are used in the ongoing European EpSSG RMS 05 (European Pediatric Soft Tissue Sarcoma Group) protocol to stratify oncologic risk and the required intensity of local and systemic therapy. Although radiation therapy as part of second-line therapy is able to cure patients after local relapse with no impact on OS, this relatively aggressive local treatment can be omitted for young patients with favorable tumor patterns: ORMS with tumor <5 cm, age below 10 years, and NPM tumor extension. Nevertheless, the psychological impact and the total cumulative dose of chemotherapy resulting from an additional line of therapy must be taken into account and discussed with families when radiotherapy is not used as part of first-line treatment. Ocular and orbital late effects are frequent after treatment of ORMS, indicating the need for systematic long-term ophthalmologic follow-up of these patients. Radiation therapy is an important part of the total burden of therapy. 25 
